To further demonstrate the contribution of SMAD3 on CCR5 regulation, we inhibited SMAD3 by pretreating breast cancer cells with SIS3, a known SMAD3 inhibitor [22], in the luciferase assay. Here, SMAD3 is linked to breast carcinoma.